BERKELEY HEIGHTS, N.J., Nov. 01, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics®, Inc. (Nasdaq:EDGE), a clinical-stage biotechnology company...
BERKELEY HEIGHTS, N.J., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a...
CUSIP NO. 279870109 &n...
BERKELEY HEIGHTS, N.J., Oct. 06, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a...
FORM 4 [ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may...
BERKELEY HEIGHTS, N.J., Sept. 20, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a...
FORM 3 UNITED STATES SECURITIES AND EXCHANGE...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 FORM...
BERKELEY HEIGHTS, N.J., Sept. 19, 2017 (GLOBE NEWSWIRE) -- Edge Therapeutics, Inc. (Nasdaq:EDGE), a...
UNITED STATES OMB APPROVAL SECURITIES AND EXCHANGE COMMISSION OMB Number: 3235-0101...
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.